Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.
Aged
Aged, 80 and over
Coronary Artery Disease
/ mortality
Drug-Eluting Stents
Dual Anti-Platelet Therapy
/ adverse effects
Female
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Prevalence
Recurrence
Registries
Retrospective Studies
Risk Assessment
Risk Factors
Sex Factors
Time Factors
Treatment Outcome
everolimus‐eluting stent
high bleeding risk
major bleeding
percutaneous coronary intervention
sex
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
07 04 2020
07 04 2020
Historique:
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
9
3
2021
Statut:
ppublish
Résumé
Background Women have been associated with higher rates of recurrent events after percutaneous coronary intervention than men, possibly attributable to advanced age at presentation and greater comorbidities. These factors also put women at higher risk of bleeding, which may influence therapeutic strategies and clinical outcomes. Methods and Results We performed a patient-level pooled analysis of 4 postapproval registries to evaluate sex-related differences in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention. HBR required fulfillment of at least 1 major or 2 minor criteria of the Academic Research Consortium definition. Outcomes of interest were major bleeding and major adverse cardiac events (composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis). Of the total 10 502 patients, 2832 (27.0%) were women. The prevalence of HBR was higher in women compared with men (29.0% versus 20.5%,
Identifiants
pubmed: 32223396
doi: 10.1161/JAHA.119.014611
pmc: PMC7428610
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e014611Références
Catheter Cardiovasc Interv. 2012 Oct 1;80(4):514-21
pubmed: 22045678
JAMA. 2002 Jan 9;287(2):210-5
pubmed: 11779263
Lancet. 2016 Nov 26;388(10060):2607-2617
pubmed: 27806902
J Am Coll Cardiol. 2010 May 4;55(18):1923-32
pubmed: 20430263
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):629-637
pubmed: 27152497
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234
pubmed: 27079334
Expert Opin Drug Saf. 2018 Oct;17(10):1041-1052
pubmed: 30223690
Eur Heart J. 2019 Aug 14;40(31):2632-2653
pubmed: 31116395
Int J Epidemiol. 2011 Feb;40(1):139-46
pubmed: 20926369
N Engl J Med. 2015 Nov 19;373(21):2038-47
pubmed: 26466021
Cardiovasc Interv Ther. 2019 Jan;34(1):40-46
pubmed: 29484580
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36
pubmed: 26965932
JACC Cardiovasc Interv. 2011 Jun;4(6):654-64
pubmed: 21700252
Catheter Cardiovasc Interv. 2015 Feb 15;85(3):359-68
pubmed: 25115966
Catheter Cardiovasc Interv. 2010 Feb 1;75(2):145-52
pubmed: 20095009
Am J Cardiol. 2009 May 1;103(9):1196-203
pubmed: 19406258
Lancet. 2018 Jan 6;391(10115):41-50
pubmed: 29102362
Indian Heart J. 2014 May-Jun;66(3):302-8
pubmed: 24973835
J Am Heart Assoc. 2014 Feb 07;3(1):e000523
pubmed: 24510115
JAMA Cardiol. 2017 Dec 1;2(12):1303-1313
pubmed: 29049508
Thromb Haemost. 2018 Nov;118(11):1997-2005
pubmed: 30312975
J Am Heart Assoc. 2020 Apr 7;9(7):e014611
pubmed: 32223396
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
J Am Soc Nephrol. 2012 Oct;23(10):1631-4
pubmed: 22935483
JACC Cardiovasc Interv. 2011 Dec;4(12):1298-309
pubmed: 22192371